Boston Scientific, The Newest Player in Gene Therapy
This article was originally published in Start Up
Executive Summary
The devices that are necessary for most gene therapy approaches put interventional device companies in a perfect position to profit from their biological discoveries. Boston Scientific Corp. is determined to be the leading light in the field, and last month it acquired gene therapy start-up CardioGene.